ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 22, 2022

Grant of Share Options

Read More
December 22, 2022

End of Year Update

Read More
November 18, 2022

Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities

Read More
September 30, 2022

Lupuzor™ Update

Read More
September 30, 2022

INTERIM RESULTS for the six months ended 30 June 2022

Read More
September 15, 2022

Written response received from the FDA

Read More
September 07, 2022

Exercise of Options | L1 Capital

Read More
August 31, 2022

FDA response for Type C Meeting – update

Read More
August 31, 2022

Exercise of Options

Read More
August 24, 2022

Exercise of Options

Read More
August 18, 2022

Lanstead Capital TR1

Read More
August 16, 2022

Total Voting Rights

Read More
  • 1
  • 2
  • 3
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved